Contact Us
.svg)
Echo Partners Advises Renew Biotechnologies on Collaboration with Mayo Clinic
Echo Partners advised Renew Biotechnologies on its clinical development collaboration with Mayo Clinic, announced by Renew on October 1, 2026. The collaboration will evaluate NeuroLens®, Renew’s cell-free DNA-based approach, in multiple sclerosis and related neuroimmunologic diseases.
Renew is a translational diagnostics company focused on disease-specific molecular signals. The research will bring together its molecular platform with Mayo Clinic’s clinical expertise and well-characterized biorepository resources to examine signals associated with central nervous system injury. Building on Renew’s prior research in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS), the collaboration will initially focus on multiple sclerosis, with potential expansion into additional neuroimmunologic diseases.
“Working with Echo Partners was a great experience. They open the right doors with strategic partners and consistently provided valuable insight and guidance as we turned initial conversations into meaningful opportunities.” - Chad Pollard, PhD, Chief Executive Officer, Renew Biotechnologies